Summary:
A 12-week multicenter study to assess the effectiveness of an investigational drug in comparison to a placebo in the treatment of insomnia. The 12 week blinded study will be followed by a 40 week open treatment phase.
Qualified Participants Must:
• Be 18 years of age or older and have primary insomnia that impacts daytime functioning
•
Have Body Mass Index must less than 32 and no history of sleep apnea, narcolepsy, or restless leg syndrome
Qualified Participants May Receive:
Study medications and physical exam at no cost. Qualified participants will receive a stipend to cover time and travel.